English

INTERIM REPORT JANUARY-MARCH 2007

Report this content

• The Group’s revenues from sales of goods and royalties amounted to 300.3 (282.2) MSEK, an increase of 6 percent.

• Growth within the Esthetics product area was 15 percent and revenues amounted to 239.9 (208.0) MSEK.

• Operating income amounted to 56.1 (56.0) MSEK.

• Net income after tax amounted to 41.7 (39.0) MSEK.

• Earnings per share after full dilution were 0.42 (0.39) kr.

• Collaboration agreement with Medy-Tox Inc. regarding the development and commercialization of botulinum toxin products.

• Exclusive distribution agreement with Medy-Tox Inc. regarding Medy-Tox’s botulinum toxin type A product for Europe, as well as a non-exclusive agreement to sell the product in Japan.

• On May 2, 2007 RESTYLANE Perlane was approved for sales in the USA.

Documents & Links